The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
Open accessAbstract
BACKGROUND: Activating mutation of KRAS and BRAF are focused on as potential prognostic and predictive biomarkers in patients with colorectal cancer (CRC) treated with anti-EGFR therapies. This study investigated the clinicopathological features and prognostic impact of KRAS/BRAF mutation in advanced and recurrent CRC patients. METHOD: Patients with advanced and recurrent CRC treated with systemic chemotherapy (n=229) were analysed for KRAS/BRAF genotypes by cycleave PCR. Prognostic factors associated with survival were identified by univariate and multivariate analyses using the Cox proportional hazards model. RESULTS: KRAS and BRAF mutations were present in 34.5% and 6.5% of patients, respectively. BRAF mutated tumours were more likely to develop on the right of the colon, and to be of the poorly differentiated adenocarcinoma or mucinous carcinoma, and peritoneal metastasis. The median overall survival (OS) for BRAF mutation-positive and KRAS 13 mutation-positive patients was 11.0 and 27.7 months, respectively, which was significantly worse than that for patients with wild-type (wt) KRAS and BRAF (40.6 months) (BRAF; HR=4.25, P<0.001, KRAS13; HR=2.03, P=0.024). After adjustment for significant features by multivariate Cox regression analysis, BRAF mutation was associated with poor OS (HR=4.23, P=0.019). CONCLUSION: Presence of mutated BRAF is one of the most powerful prognostic factors for advanced and recurrent CRC. The KRAS13 mutation showed a trend towards poor OS in patients with advanced and recurrent CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,636
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Jass, J. R. (2007) · Histopathology · doi:10.1111/j.1365-2559.2006.02549.x · Cited by 1,384
RAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224 · cited 2×
“None of the CRC patients in our study carried both KRAS and BRAF mutations, supporting the hypothesis that KRAS and BRAF mutations occur in a mutually exclusive manner (Rajagopalan et al, 2002; Frattini et al, 2004; Ahlquist et al, 2008).”
BackgroundResultThe MAPK signalling pathways and colorectal cancer
Fang, J. Y., & Richardson, B. C. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70168-6 · Cited by 1,185
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158
The Genetic Basis of Human Cancer
Vogelstein, B., & Kinzler, K. W. (1997) · Cited by 1,120
Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S., Siena, S., & Bardelli, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4158 · Cited by 830
Ogino, S., Nosho, K., Kirkner, G. J., Kawasaki, T., Meyerhardt, J. A., Loda, M., Giovannucci, E. L., & Fuchs, C. S. (2009) · Gut · doi:10.1136/gut.2008.155473 · Cited by 777
Kirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study
Andreyev, H. J. N., Norman, A. R., Clarke, P. A., Cunningham, D., & Oates, J. R. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.675 · Cited by 748
Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.-B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6796 · Cited by 673
Loupakis, F., Ruzzo, A., Cremolini, C., Vincenzi, B., Salvatore, L., Santini, D., Masi, G., Stasi, I., Canestrari, E., Rulli, E., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605177 · Cited by 564
Carey, K. D., Garton, A. J., Romero, M. S., Kahler, J., Thomson, S., Ross, S., Park, F., Haley, J. D., Gibson, N., & Sliwkowski, M. X. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0453 · Cited by 445
BRAF Mutation in Metastatic Colorectal Cancer
Tol, J., Nagtegaal, I. D., & Punt, C. J. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0904160 · Cited by 445
The Genetic Basis of Human Cancer
Rubin, C. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-9-199811010-00045 · Cited by 411
Souglakos, J., Philips, J., Wang, R., Marwah, S., Silver, M., Tzardi, M., Silver, J., Ogino, S., Hooshmand, S., Kwak, E., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605164 · Cited by 310
Fariña-Sarasqueta, A., van Lijnschoten, G., Moerland, E., Creemers, G.-J., Lemmens, V. E. P. P., Rutten, H. J. T., & van den Brule, A. J. C. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq258 · Cited by 263
Ogino, S., Brahmandam, M., Cantor, M., Namgyal, C., Kawasaki, T., Kirkner, G., Meyerhardt, J. A., Loda, M., & Fuchs, C. S. (2006) · Modern Pathology · doi:10.1038/modpathol.3800482 · Cited by 252
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer
French, A. J., Sargent, D. J., Burgart, L. J., Foster, N. R., Kabat, B. F., Goldberg, R., Shepherd, L., Windschitl, H. E., & Thibodeau, S. N. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1489 · Cited by 251
Different Genetic Features Associated with Colon and Rectal Carcinogenesis
Frattini, M., Balestra, D., Suardi, S., Oggionni, M., Alberici, P., Radice, P., Costa, A., Daidone, M. G., Leo, E., Pilotti, S., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0031 · Cited by 228
Bazan, V., Migliavacca, M., Zanna, I., Tubiolo, C., Grassi, N., Latteri, M. A., La Farina, M., Albanese, I., Dardanoni, G., Salerno, S., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf226 · Cited by 225
Catalano, V, Loupakis, F., Graziano, F., Torresi, U., Bisonni, R., Mari, D., Fornaro, L., Baldelli, A. M., Giordani, P., Rossi, D., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604955 · Cited by 190
Bennecke, M., Kriegl, L., Bajbouj, M., Retzlaff, K., Robine, S., Jung, A., Arkan, M. C., Kirchner, T., & Greten, F. R. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.013 · Cited by 186
A Rapid, Sensitive Assay to Detect EGFR Mutation in Small Biopsy Specimens from Lung Cancer
Yatabe, Y., Hida, T., Horio, Y., Kosaka, T., Takahashi, T., & Mitsudomi, T. (2006) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2006.050104 · Cited by 185
Self-citationZlobec, I., Bihl, M. P., Schwarb, H., Terracciano, L., & Lugli, A. (2010) · International Journal of Cancer · doi:10.1002/ijc.25042 · Cited by 172
Sakamoto, H., Shimizu, J., Horio, Y., Ueda, R., Takahashi, T., Mitsudomi, T., & Yatabe, Y. (2007) · The Journal of Pathology · doi:10.1002/path.2165 · Cited by 129
Self-citationZlobec, I., Kovac, M. B., Erzberger, P., Molinari, F., Bihl, M., Rufle, A., Foerster, A., Frattini, M., Terracciano, L., Heinimann, K., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25265 · Cited by 108
Mutant KRAS, chromosomal instability and prognosis in colorectal cancer
Castagnola, P., & Giaretti, W. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.06.003 · Cited by 91
Bokemeyer, C., Köhne, C. H., Rougier, P. R., Stroh, C., Schlichting, M., & Cutsem, E. V. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3506 · Cited by 85
Deng, G., Kakar, S., Tanaka, H., Matsuzaki, K., Miura, S., Sleisenger, M. H., & Kim, Y. S. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.03.014 · Cited by 68
RAS Signaling in Colorectal Carcinomas through Alteration of RAS, RAF, NF1, and/or RASSF1A
Ahlquist, T. C., Bottillo, I., Danielsen, S. A., Meling, G. I., Rognum, T. O., Lind, G. E., Dallapiccola, B., & Lothe, R. A. (2008) · Neoplasia · doi:10.1593/neo.08312 · Cited by 57
Kakar, S., Deng, G., Sahai, V., Matsuzaki, K., Tanaka, H., Miura, S., & Kim, Y. S. (2008) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2008-132-958-cccimp · Cited by 51
Kim, I.-J., Kang, H. C., Jang, S., Kim, K. H., Ahn, S.-A., Yoon, H., Yoon, S. N., & Park, J.-G. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi237 · Cited by 38
Yokota, T., Shibata, N., Ura, T., Takahari, D., Shitara, K., Muro, K., & Yatabe, Y. (2010) · Translational research · doi:10.1016/j.trsl.2010.05.007 · Cited by 27
Self-citation
Cited by
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467
Self-citationHashiguchi, Y., Muro, K., Saito, Y., Ito, Y., Ajioka, Y., Hamaguchi, T., Hasegawa, K., Hotta, K., Ishida, H., Ishiguro, M., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01485-z · Cited by 1,922
Self-citationYoshino, T., Arnold, D., Taniguchi, H., Pentheroudakis, G., Yamazaki, K., Xu, R.-H., Kim, T. W., Ismail, F., Tan, I. B., Yeh, K.-H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx738 · Cited by 573
Self-citationCorcoran, R. B., Atreya, C. E., Falchook, G. S., Kwak, E. L., Ryan, D. P., Bendell, J. C., Hamid, O., Messersmith, W. A., Daud, A., Kurzrock, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2471 · Cited by 507
Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
Lochhead, P., Kuchiba, A., Imamura, Y., Liao, X., Yamauchi, M., Nishihara, R., Qian, Z. R., Morikawa, T., Shen, J., Meyerhardt, J. A., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt173 · Cited by 442
Metadata
- Authors
- Yokota, T., Ura, T., Shibata, N., Takahari, D., Shitara, K., Nomura, M., Kondo, C., Mizota, A., Utsunomiya, S., Muro, K., & Yatabe, Y.
- Venue
- British Journal of Cancer
- Published
- 2011-02-01
- Volume
- 104
- Issue
- 5
- Pages
- 856-862
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1985645498
- Cited by
- 401
- References
- 38
- FWCI
- 15.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.